健友股份(603707.SH)子公司获得美国FDA醋酸奥曲肽注射液药品增加生产场地注册批件

Core Viewpoint - The company, Jianyou Co., Ltd. (603707.SH), announced that its subsidiary, Meitheal Pharmaceuticals, Inc., received approval from the U.S. Food and Drug Administration (FDA) to increase production sites for Acetate Octreotide Injection in various concentrations, which is expected to positively impact the company's operational performance [1] Group 1 - Meitheal Pharmaceuticals, Inc. received FDA approval for Acetate Octreotide Injection in concentrations of 50 mcg/mL, 100 mcg/mL, and 500 mcg/mL [1] - The approval includes the production site located at Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. [1] - The newly approved product is scheduled for market launch in the U.S. [1]